WallStSmart

Abbott Laboratories (ABT)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 4365% more annual revenue ($46.59B vs $1.04B). ABT leads profitability with a 11.7% profit margin vs -2.7%. ABT earns a higher WallStSmart Score of 49/100 (D+).

ABT

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LMRI

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 7/9Altman Z: 0.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-57.6%)

Margin of Safety

-57.6%

Fair Value

$74.02

Current Price

$111.56

$37.54 premium

UndervaluedFair: $74.02Overvalued

Intrinsic value data unavailable for LMRI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$190.98B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

LMRI2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.244/10

Expensive relative to growth rate

P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

LMRI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.19B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Return on EquityProfitability
-10.0%2/10

ROE of -10.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : LMRI

The strongest argument for LMRI centers on Debt/Equity, Price/Book.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : LMRI

The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while LMRI is a turnaround play — different risk/reward profiles.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (49/100 vs 35/100) and 13.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Lumexa Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.

Want to dig deeper into these stocks?